Browse by Author

Browse by Year

Browsing publications by Dr David Jamieson

Newcastle AuthorsTitleYearFull text
Dr David Jamieson
Dr Nicola Sunter
Sara Muro
Dr Nicola Cresti
Julieann Sludden
et al.
Pharmacogenetic association of MBL2 and CD95 polymorphisms with grade 3 infection following adjuvant therapy for breast cancer with doxorubicin and cyclophosphamide2017
Professor Edvaldo Ribeiro Rosa
Dr Deepali Pal
Dr David Jamieson
Kenneth Rankin
Dr Matthew Benning
et al.
Temporary Single Cell Coating for Bioprocessing via a Cationic Polymer2017
Dr David Jamieson
Melanie Griffin
Julieann Sludden
Dr Yvette Drew
Dr Nicola Cresti
et al.
A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours2016
Dr David Jamieson
Condensin II mutation causes T-cell lymphoma through tissue-specific genome instability2016
Dr Gareth Veal
Julieann Sludden
Dr David Jamieson
Julie Errington
Dr Ghada Malik
et al.
Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin’s lymphoma2016
Dr Nicola Cresti
Dr Despina Televantou
Dr David Jamieson
Dr Mark Verrill
Professor Alan Boddy
et al.
Genetic variants in the HER2 gene: Influence on HER2 overexpression and loss of heterozygosity in breast cance2016
Barry Dent
Laura Ogle
Dr Rachel O'Donnell
Dr Ujjal Mallick
Professor Nicola Curtin
et al.
High-resolution imaging for the detection and characterisation of circulating tumour cells from patients with oesophageal, hepatocellular, thyroid and ovarian cancers2016
Laura Ogle
Dr James Orr
Catherine Willoughby
Dr Claire Hutton
Dr Stuart McPherson
et al.
Imagestream detection and characterisation of circulating tumour cells - a liquid biopsy for Hepatocellular Carcinoma?2016
Angharad Humphreys
Dr Alem Gabriel
Dr Nicholas Bown
Dr Lindi Chen
Dr David Jamieson
et al.
Imaging flow-cytometer based detection of ALK and MDM2 amplification in neuroblastoma cell lines2016
Dr Yvette Drew
Dr Martin Highley
Julieann Sludden
Dr James Murray
Dr David Jamieson
et al.
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly (ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer2016
1234